Increased IFN-β secretion and clonal expansion of tumor-derived T-cell receptors (TCRs) predicted responsiveness to this combination therapy (Formenti et al. 2018), thereby highlighting the potential of radiotherapy to induce type I IFN responses promoting innate antitumor immunogenicity. This evidence concerns the gene IFNB1 and neoplasm.